Surrey researchers Sign in
Back
Real world evidence on prescribing trends in sodium glucose co-transporter 2 inhibitors in UK primary care
Conference presentation   Peer reviewed

Real world evidence on prescribing trends in sodium glucose co-transporter 2 inhibitors in UK primary care

A McGovern, W Hinton, J van Vlymen, N Munro, MB Whyte and S de Lusignan
Diabetic Medicine, Volume 33, Issue Supplement S1, March 2016 Special Issue: Abstracts of the Diabetes UK Professional Conference 2016, Vol.33(Supple), pp.165-165
Diabetes UK Professional Conference 2016 (Scottish Exhibition and Conference Centre, Glasgow, 2-4 March 2016, 02/03/2016 - 04/03/2016)
03/2016
DOI: https://doi.org/10.1111/dme.45_13048

Abstract

Nutrition
Aims: The sodium glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral diabetes medication. Prescribing of these agents was initially limited to secondary care but is now moving into primary care. We analyse the current use of this drug class in primary care.
url
http://www.mcgov.co.uk/publicwork/View
Author

Metrics

50 Record Views

Details

Usage Policy

Usage details for all content viewed and downloaded in this site are shared with IRUS-UK (Institutional Repository Usage Statistics UK). Cookies are used to remember your decision. Click Accept to accept usage details sharing and the cookies.

Learn more